PP
KRTX

Paloma Partners’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Paloma Partners’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,361
Closed -$284K – 2376
2021
Q1 		$284K Buy
+2,361
New +$267K 0.01% 1533

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Paloma Partners's KRTX Position: Q2 2021 in Review

Paloma Partners sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2021, closing a stake of 2,361 shares — an estimated $284K sold.

Paloma Partners first reported a position in KRTX in Q1 2021 and held it in 1 quarter. The position peaked at $284K in Q1 2021. 159 funds tracked by Wall St. Rank hold KRTX as of Q2 2021.

  • Paloma Partners reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Paloma Partners sold 2,361 Karuna Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $284K.
  • Paloma Partners first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Paloma Partners's Karuna Therapeutics, Inc. Common Stock position peaked at $284K in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Paloma Partners's 13F filing for Q2 2021, filed 16 Aug 2021.